Oculis Holding AG
OCS · XNASCIK 1953530fmd_05VH66ZTGJTE69VQSCYTJ93T43Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 9 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 9 | 10 | 22 | 29 | 52 | 57 |
| Operating income | (12) | (13) | (32) | (81) | (73) | (82) |
| Interest expense | 3 | 5 | 6 | 1 | 1 | 1 |
| Income before taxes | (15) | (19) | (39) | (89) | (86) | (99) |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | (0) |
| Net income from continuing operations | (15) | (19) | (39) | (89) | (86) | (99) |
| Net income | (15) | (19) | (39) | (89) | (86) | (99) |